Risk of Myocardial Infarction Among New Users of Calcium Supplements Alone or Combined With Vitamin D: A Population‐Based Case‐Control Study

A population‐based case‐control study was conducted to evaluate the risk of acute myocardial infarction among new users of calcium supplements either in monotherapy (CaM) or in combination with vitamin D (CaD). A total of 23,025 cases and 114,851 controls randomly sampled from the underlying cohort...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical pharmacology and therapeutics 2020-02, Vol.107 (2), p.359-368
Hauptverfasser: Rodríguez‐Martín, Sara, González‐Bermejo, Diana, Rodríguez‐Miguel, Antonio, Barreira, Diana, García‐Lledó, Alberto, Gil, Miguel, Abajo, Francisco J.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 368
container_issue 2
container_start_page 359
container_title Clinical pharmacology and therapeutics
container_volume 107
creator Rodríguez‐Martín, Sara
González‐Bermejo, Diana
Rodríguez‐Miguel, Antonio
Barreira, Diana
García‐Lledó, Alberto
Gil, Miguel
Abajo, Francisco J.
description A population‐based case‐control study was conducted to evaluate the risk of acute myocardial infarction among new users of calcium supplements either in monotherapy (CaM) or in combination with vitamin D (CaD). A total of 23,025 cases and 114,851 controls randomly sampled from the underlying cohort and matched with cases by age, sex, and index date were included. New users of CaM and CaD were categorized as current users, recent users, past users, and nonusers. We computed adjusted odds ratios (AORs) and their 95% confidence intervals (CIs) among current users as compared with nonusers through a conditional logistic regression. No increased risk was associated with CaM overall (59 cases (0.26%) and 273 controls (0.24%); AOR = 0.80; 95% CI 0.59–1.09), nor was it found in any of the conditions examined. Instead, the use of CaD was associated with a decreased risk (275 cases (1.19%) and 1,160 controls (1.45%); AOR = 0.78; 95% CI 0.67–0.90), dose and duration‐dependent, and particularly evident in patients with a high cardiovascular risk (AOR = 0.59; 95% CI 0.43–0.81).
doi_str_mv 10.1002/cpt.1636
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7006888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2299139108</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4106-c47327ce6179f536edbc516cb457edb78cd3a6abe4776e01571072ebe9f719953</originalsourceid><addsrcrecordid>eNp1kc1u1TAQRi0EorcFiSdAXrJJsePEjlkgXcJfpQIVbWFpOc6kNTh2sJNWd8cj9Bl5EnxpqcqCzdijOTr26EPoCSX7lJDyuZnmfcoZv4dWtGZlwWtW30crQogsZMn4DtpN6VtuK9k0D9EOozUnFWUrdPXZpu84DPjDJhgde6sdPvCDjma2weP1GPwZ_giX-DRBTFuw1c7YZcTHyzQ5GMHPCa9d8IBDxG0YO-uhx1_tfI6_2FmP1uPXL_AaH4VpcXpr_fXz6pVOGWpzzU0b_ByDw8fz0m8eoQeDdgke35x76PTtm5P2fXH46d1Buz4sTEUJz1WwUhjgVMihZhz6ztSUm66qRb6LxvRMc91BJQQHQmtBiSihAzkIKmXN9tDLa--0dCP0Ju8RtVNTtKOOGxW0Vf9OvD1XZ-FCCUJ40zRZ8OxGEMOPBdKsRpsMOKc9hCWpspSSMknJHdTEkFKE4fYZStQ2QJUDVNsAM_r07rduwb-JZaC4Bi6tg81_Rao9Ovkj_A2Yl6iV</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2299139108</pqid></control><display><type>article</type><title>Risk of Myocardial Infarction Among New Users of Calcium Supplements Alone or Combined With Vitamin D: A Population‐Based Case‐Control Study</title><source>Wiley Online Library All Journals</source><creator>Rodríguez‐Martín, Sara ; González‐Bermejo, Diana ; Rodríguez‐Miguel, Antonio ; Barreira, Diana ; García‐Lledó, Alberto ; Gil, Miguel ; Abajo, Francisco J.</creator><creatorcontrib>Rodríguez‐Martín, Sara ; González‐Bermejo, Diana ; Rodríguez‐Miguel, Antonio ; Barreira, Diana ; García‐Lledó, Alberto ; Gil, Miguel ; Abajo, Francisco J.</creatorcontrib><description>A population‐based case‐control study was conducted to evaluate the risk of acute myocardial infarction among new users of calcium supplements either in monotherapy (CaM) or in combination with vitamin D (CaD). A total of 23,025 cases and 114,851 controls randomly sampled from the underlying cohort and matched with cases by age, sex, and index date were included. New users of CaM and CaD were categorized as current users, recent users, past users, and nonusers. We computed adjusted odds ratios (AORs) and their 95% confidence intervals (CIs) among current users as compared with nonusers through a conditional logistic regression. No increased risk was associated with CaM overall (59 cases (0.26%) and 273 controls (0.24%); AOR = 0.80; 95% CI 0.59–1.09), nor was it found in any of the conditions examined. Instead, the use of CaD was associated with a decreased risk (275 cases (1.19%) and 1,160 controls (1.45%); AOR = 0.78; 95% CI 0.67–0.90), dose and duration‐dependent, and particularly evident in patients with a high cardiovascular risk (AOR = 0.59; 95% CI 0.43–0.81).</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1002/cpt.1636</identifier><identifier>PMID: 31560413</identifier><language>eng</language><publisher>United States: John Wiley and Sons Inc</publisher><ispartof>Clinical pharmacology and therapeutics, 2020-02, Vol.107 (2), p.359-368</ispartof><rights>2019 The Authors. published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.</rights><rights>2019 The Authors. Clinical Pharmacology &amp; Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4106-c47327ce6179f536edbc516cb457edb78cd3a6abe4776e01571072ebe9f719953</citedby><cites>FETCH-LOGICAL-c4106-c47327ce6179f536edbc516cb457edb78cd3a6abe4776e01571072ebe9f719953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcpt.1636$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcpt.1636$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31560413$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rodríguez‐Martín, Sara</creatorcontrib><creatorcontrib>González‐Bermejo, Diana</creatorcontrib><creatorcontrib>Rodríguez‐Miguel, Antonio</creatorcontrib><creatorcontrib>Barreira, Diana</creatorcontrib><creatorcontrib>García‐Lledó, Alberto</creatorcontrib><creatorcontrib>Gil, Miguel</creatorcontrib><creatorcontrib>Abajo, Francisco J.</creatorcontrib><title>Risk of Myocardial Infarction Among New Users of Calcium Supplements Alone or Combined With Vitamin D: A Population‐Based Case‐Control Study</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>A population‐based case‐control study was conducted to evaluate the risk of acute myocardial infarction among new users of calcium supplements either in monotherapy (CaM) or in combination with vitamin D (CaD). A total of 23,025 cases and 114,851 controls randomly sampled from the underlying cohort and matched with cases by age, sex, and index date were included. New users of CaM and CaD were categorized as current users, recent users, past users, and nonusers. We computed adjusted odds ratios (AORs) and their 95% confidence intervals (CIs) among current users as compared with nonusers through a conditional logistic regression. No increased risk was associated with CaM overall (59 cases (0.26%) and 273 controls (0.24%); AOR = 0.80; 95% CI 0.59–1.09), nor was it found in any of the conditions examined. Instead, the use of CaD was associated with a decreased risk (275 cases (1.19%) and 1,160 controls (1.45%); AOR = 0.78; 95% CI 0.67–0.90), dose and duration‐dependent, and particularly evident in patients with a high cardiovascular risk (AOR = 0.59; 95% CI 0.43–0.81).</description><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp1kc1u1TAQRi0EorcFiSdAXrJJsePEjlkgXcJfpQIVbWFpOc6kNTh2sJNWd8cj9Bl5EnxpqcqCzdijOTr26EPoCSX7lJDyuZnmfcoZv4dWtGZlwWtW30crQogsZMn4DtpN6VtuK9k0D9EOozUnFWUrdPXZpu84DPjDJhgde6sdPvCDjma2weP1GPwZ_giX-DRBTFuw1c7YZcTHyzQ5GMHPCa9d8IBDxG0YO-uhx1_tfI6_2FmP1uPXL_AaH4VpcXpr_fXz6pVOGWpzzU0b_ByDw8fz0m8eoQeDdgke35x76PTtm5P2fXH46d1Buz4sTEUJz1WwUhjgVMihZhz6ztSUm66qRb6LxvRMc91BJQQHQmtBiSihAzkIKmXN9tDLa--0dCP0Ju8RtVNTtKOOGxW0Vf9OvD1XZ-FCCUJ40zRZ8OxGEMOPBdKsRpsMOKc9hCWpspSSMknJHdTEkFKE4fYZStQ2QJUDVNsAM_r07rduwb-JZaC4Bi6tg81_Rao9Ovkj_A2Yl6iV</recordid><startdate>202002</startdate><enddate>202002</enddate><creator>Rodríguez‐Martín, Sara</creator><creator>González‐Bermejo, Diana</creator><creator>Rodríguez‐Miguel, Antonio</creator><creator>Barreira, Diana</creator><creator>García‐Lledó, Alberto</creator><creator>Gil, Miguel</creator><creator>Abajo, Francisco J.</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202002</creationdate><title>Risk of Myocardial Infarction Among New Users of Calcium Supplements Alone or Combined With Vitamin D: A Population‐Based Case‐Control Study</title><author>Rodríguez‐Martín, Sara ; González‐Bermejo, Diana ; Rodríguez‐Miguel, Antonio ; Barreira, Diana ; García‐Lledó, Alberto ; Gil, Miguel ; Abajo, Francisco J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4106-c47327ce6179f536edbc516cb457edb78cd3a6abe4776e01571072ebe9f719953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rodríguez‐Martín, Sara</creatorcontrib><creatorcontrib>González‐Bermejo, Diana</creatorcontrib><creatorcontrib>Rodríguez‐Miguel, Antonio</creatorcontrib><creatorcontrib>Barreira, Diana</creatorcontrib><creatorcontrib>García‐Lledó, Alberto</creatorcontrib><creatorcontrib>Gil, Miguel</creatorcontrib><creatorcontrib>Abajo, Francisco J.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rodríguez‐Martín, Sara</au><au>González‐Bermejo, Diana</au><au>Rodríguez‐Miguel, Antonio</au><au>Barreira, Diana</au><au>García‐Lledó, Alberto</au><au>Gil, Miguel</au><au>Abajo, Francisco J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk of Myocardial Infarction Among New Users of Calcium Supplements Alone or Combined With Vitamin D: A Population‐Based Case‐Control Study</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2020-02</date><risdate>2020</risdate><volume>107</volume><issue>2</issue><spage>359</spage><epage>368</epage><pages>359-368</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><abstract>A population‐based case‐control study was conducted to evaluate the risk of acute myocardial infarction among new users of calcium supplements either in monotherapy (CaM) or in combination with vitamin D (CaD). A total of 23,025 cases and 114,851 controls randomly sampled from the underlying cohort and matched with cases by age, sex, and index date were included. New users of CaM and CaD were categorized as current users, recent users, past users, and nonusers. We computed adjusted odds ratios (AORs) and their 95% confidence intervals (CIs) among current users as compared with nonusers through a conditional logistic regression. No increased risk was associated with CaM overall (59 cases (0.26%) and 273 controls (0.24%); AOR = 0.80; 95% CI 0.59–1.09), nor was it found in any of the conditions examined. Instead, the use of CaD was associated with a decreased risk (275 cases (1.19%) and 1,160 controls (1.45%); AOR = 0.78; 95% CI 0.67–0.90), dose and duration‐dependent, and particularly evident in patients with a high cardiovascular risk (AOR = 0.59; 95% CI 0.43–0.81).</abstract><cop>United States</cop><pub>John Wiley and Sons Inc</pub><pmid>31560413</pmid><doi>10.1002/cpt.1636</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-9236
ispartof Clinical pharmacology and therapeutics, 2020-02, Vol.107 (2), p.359-368
issn 0009-9236
1532-6535
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7006888
source Wiley Online Library All Journals
title Risk of Myocardial Infarction Among New Users of Calcium Supplements Alone or Combined With Vitamin D: A Population‐Based Case‐Control Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T09%3A43%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20of%20Myocardial%20Infarction%20Among%20New%20Users%20of%20Calcium%20Supplements%20Alone%20or%20Combined%20With%20Vitamin%20D:%20A%20Population%E2%80%90Based%20Case%E2%80%90Control%20Study&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Rodr%C3%ADguez%E2%80%90Mart%C3%ADn,%20Sara&rft.date=2020-02&rft.volume=107&rft.issue=2&rft.spage=359&rft.epage=368&rft.pages=359-368&rft.issn=0009-9236&rft.eissn=1532-6535&rft_id=info:doi/10.1002/cpt.1636&rft_dat=%3Cproquest_pubme%3E2299139108%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2299139108&rft_id=info:pmid/31560413&rfr_iscdi=true